The ‘plastic spoon' of microplastics in your brain could stem from these foods that are wrecking your health, researchers say
Not only were there more microplastics in the brain than in liver or kidney tissue, but microplastic concentrations were higher in the brains of dementia patients than in those without it.
Now, scientists are examining the effect on brain health of microplastics and one of the largest sources of microplastics: ultra-processed foods (UPFs). In a series of four papers published in the journal Brain Medicine, researchers synthesize mounting evidence that microplastics accumulating in the brain—especially those from UPFs—could be contributing to rising global rates of dementia, depression, and other mental health disorders.
'We're seeing converging evidence that should concern us all,' said co-author of one of the papers, Dr. Nicholas Fabiano from the University of Ottawa, in the press release.
'Ultra-processed foods now comprise more than 50% of energy intake in countries like the United States, and these foods contain significantly higher concentrations of microplastics than whole foods,' Fabiano said. 'Recent findings show these particles can cross the blood-brain barrier and accumulate in alarming quantities.'
The researchers consolidate the science linking UPF consumption with adverse mental health, and how that overlaps with microplastic accumulation in the brain. For instance, they cite a 2024 umbrella review published in the British Medical Journal which found that people who consumed ultra-processed foods had a 22% higher risk of depression, 48% higher risk of anxiety, and 41% higher risk of poor sleep.
In the papers, the researchers hypothesize that microplastics could be the missing link in UPFs' impact on brain health, by connecting it to data such as UPFs like chicken nuggets contain 30 times more microplastics per gram than chicken breasts—highlighting how processing could increase microplastic content.
'Ultra-processed foods have been linked to adverse mental health through inflammation, oxidative stress, epigenetics, mitochondrial dysfunction, and disruptions to neurotransmitter systems. Microplastics appear to operate through remarkably similar pathways,' said Wolfgang Marx from Deakin University's Food & Mood Center in Australia.
Microplastics can increase inflammation in the brain as they cross the blood-brain barrier, as a 2023 study on mice found, which can put people at risk of neurological disease and degeneration, including Alzheimer's.
'What emerges from this work is not a warning. It is a reckoning,' wrote Dr. Ma-Li Wong, professor of neuroscience at Upstate Medical University in New York. 'The boundary between internal and external has failed. If microplastics cross the blood-brain barrier, what else do we think remains sacred?'
Researchers are now looking to understand to what extent ultra-processed foods are responsible for adverse brain health outcomes, and what to do about it. The authors propose the development of a Dietary Microplastic Index, which would quantify people's exposure through food consumption.
'While we need to reduce our exposure to microplastics through better food choices and packaging alternatives, we also need research into how to remove these particles from the human body,' noted Dr. Stefan Bornstein in his paper. One of those potential methods, Bornstein proposes, is apheresis, a process of removing blood from the body and filtering out the microplastics—but he points out that more research is still needed.
'As the levels of ultra-processed foods, microplastics, and adverse mental health outcomes simultaneously rise, it is imperative that we further investigate this potential association,' said Fabiano. 'After all, you are what you eat.'
For more on microplastics:
Microplastics are everywhere. Here are 5 ways to reduce your exposure
Chewing gum is shedding harmful microplastics into your saliva, study finds
Tea bags and these 11 foods are likely exposing you to billions of microplastics
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
a day ago
- Time Business News
D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis
D Dimer Test is a kind of blood test detecting the presence of D-dimer in the blood. D-dimer is a protein fragment of fibrin formed after Fibrinolysis degradation of blood clot. It is helpful to diagnose the conditions with abnormal blood clots formation and breakdown, intravascular fibrinolysis, and coagulation. High D-dimer levels indicate clinical suspicion of a blood clot and needs ultrasound, CT angiography, scans could be performed to confirm the presence of clot and location of clot. D-Dimer test is not specific to any disease. D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies. Key Growth Drivers and Opportunities Demand for D-Dimer Testing: Traditional testing is replaced by D-dimer testing, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Moreover, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test. Rising Genetic Disorders: Increasing cases of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test globally. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test widening scope for these tests. Challenges The major challenge consists of inadequate skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths. Innovation and Expansion Study Links Long COVID Brain Fog to Blood Microclots In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and 'micro clots' in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs. Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients. LumiraDx Expands Rapid Testing for VTE and Heart Failure In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens. Inventive Sparks, Expanding Markets The major companies present in the D-dimer test market are Bio/Data Corporation, Becton Dickinson BV, Sysmex Corporation, Abbott Laboratories, Inc., Dickinson and Company, Hoffman-La Roche Ltd., among others. Global companies work to foster lasting innovation, grow their markets, and provide quality goods and services. They concentrate on improving customer experience, applying tech, and creating strong operations. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Axios
2 days ago
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
Yahoo
2 days ago
- Yahoo
This diet led to twice the fat loss in 8 weeks
Ah, UPFs (ultra-processed foods) – you're likely tired of hearing about them now. But, as they're increasingly linked to poor health outcomes like cardiovascular disease, obesity, diabetes, some types of cancer and depression, the extensive coverage is generally well-deserved. And now, in the longest ever experimental study of a UPF diet, researchers have highlighted how food processing, not just nutrients, can affect body weight and health outcomes. What did the study find? Led by researchers at UCL and UCLA, the study compared a minimally processed diet (meals included overnight oats or homemade bolognese) with an ultra-processed diet (think breakfast oat bars and ready-made lasagne). The researchers split 55 adults into two groups, with each group completing one eight-week diet before switching to the other after a washout period, during which they followed their normal diet. Both diets followed the Eatwell Guide – the UK's official government advice on how to eat a healthy, balanced diet. Participants were sent more than enough food and told to eat as they normally would – with no restriction. Interestingly, after eight weeks on the diet, both groups lost weight, potentially due to the improved nutritional profile of what they were eating compared to their normal diet. However, on the MPF diet, participants experienced a 2.06% reduction compared to a 1.05% reduction on the UPF diet. In other words, they lost twice as much weight. What's more, the greater weight loss on the MPF diet came from reduced fat mass and total body water with no change in muscle or fat-free mass, suggesting a healthier body composition overall. 'Though a 2% reduction may not seem very big, that is only over eight weeks and without people trying to actively reduce their intake,' the study's lead author Dr Samuel Dicken said of the results. If we scaled these results up over the course of a year, we'd expect to see a 13% weight reduction in men and a 9% reduction in women on the minimally processed diet.' What does this mean for us? The findings suggest that following a diet containing mostly minimally processed food supports sustainable weight loss. This makes sense since such foods tend to be more satiating and less energy-dense, which can often lead to people eating less naturally without restricting in any way. Indeed, the researchers also found that there were significantly greater improvements in the number of cravings and ability to resist them on the MPF diet compared to the UPF diet. It's certainly not to say UPF bars and snacks (which can be useful sources of fuel, especially in a workout context) are off-limits. In fact, the findings support the idea that not all UPFs are inherently unhealthy – particularly when they adhere to appropriate nutritional guidelines. The bottom line To further consolidate these results, as is often the case, more research is needed and on a larger scale. However, considering this was the first ever interventional study comparing UPF and MPF diets, the findings are valuable and demonstrate just how powerful a role food and nutrition can play in supporting sustainable weight loss and healthy body composition. You Might Also Like 13 Buys To Help You Feel Great From £5 16 Speedo Swimsuits that Won't Flash Your Bum When Getting Swim-fit 11 Best Gym Trainers for Different Types of Workouts
